Introduction
Increasing studies demonstrated that epigenetics plays a crucial role in cancer occurrence and progression [1, 2]. Different to genetic alterations, epigenetic modifications are reversible and inheritable processes which regulate gene expression without DNA sequences changes [3, 4]. Although the scope of epigenetics is not fully explored, it is commonly defined as chemical modifications, including chromatin rearrangement, DNA and RNA methylation, non-coding RNA and histone modification [5]. Previous reports mainly focused on the biological functions of DNA methylation, non-coding RNAs regulation and histone modification [6–8]. Recently, mounting studies have identified more than 100 kinds of chemical modifications in RNA, which exploits a new research field of epigenetic regulation controlled by RNA modification [9–11]. RNA methylation is the main form of RNA modifications, including N6-methyladenosine (m6A), m1A, 1-methylguanosine (m1G), m2G, m6G, m7G, 5-methylcytosine (m5C), 2’-O-methylation (Nm), pseudouridine (Ψ) and Inosine (I), among which m6A modification is the most abundant kind accounting for approximately half of all RNA methylation modifications [5, 12–14]. m6A modification exists in nearly all eukaryotes and in a part of viruses, yeasts, bacteria, and plants [12]. m6A binding sites are found in the RRACH sequence (R=A/G, H=A/C/U) and are mainly enriched in the 3’ untranslated regions (UTRs) near the stop codon of mRNA exon [12, 15]. Remarkably, m6A mediated-RNA epigenetics modification plays an important role in gastrointestinal cancer.
role in controlling physiological activities, such as embryonic stem cell differentiation, DNA repair, meiosis, tissue remodeling, and circadian rhythm, etc. [11, 16]. Dysregulation of m6A modification gives rise to multiple pathological processes, including tumorigenesis and development [14, 17, 18].

**Composition of m6A**

As a dynamic and reversible process, m6A modification can be catalyzed by m6A methyltransferases (“writer”) and eliminated by demethylases (“eraser”) [19–21]. Moreover, RNA-binding proteins (“reader”) specifically recognize and bind to m6A sites to regulate fate of RNAs (Fig. 1) [16, 19, 22].

**Writer**

“Writer” regulators traditionally consist of methyltransferase-like 3/14/16 (METTL3/14/16), WT1-associated protein (WTAP), zinc finger CCCH-type containing 13 (ZC3H13), virlike m6A methyltransferase-associated (VIRMA/KIAA1429), RNA-binding motif protein 15/15B (RBM15/15B), and Fl(2)d-associated complex component (Flacc) [15, 22–29]. Among them, METTL3 is the first identified m6A methyltransferase and exerts catalytic function with the assistance of METTL14, which stabilizes METTL3 and recognizes target RNAs [30–33]. METTL3 and METTL14 form a stable methyltransferase complex, while WTAP interacts with the heterodimer complex and ensures it to be localized in the nuclear spots and triggers catalytic activity [34–36]. METTL16 can function alone and control m6A modification in mRNAs, U6-snRNA and long noncoding RNAs [27, 29, 37–39]. RBM15, VIRMA and ZC3H13 modulate region-selective m6A methylation modification by binding to methyltransferase complex and localizing it to special RNA sites [40–42].

**Eraser**

m6A methylation can be eliminated via demethylation, which is mediated by demethylases, also called “eraser”, including Fat mass and obesity-associated protein (FTO) and AlkB homolog 3/5 RNA demethylase (ALKBH3/5)
FTO is identified as the first “eraser” and mainly influence mRNA stability, translation and splicing by regulating m6A demethylation [44, 45]. As the homologue of FTO, ALKBH3 and ALKBH5 principally mediate the transport, metabolism, and assembly of mRNA [46–48]. These erasers promote the transformation of m6A into N6-hydroxymethyladenosine and N6-formyladenosine successively, which is finally hydrolyzed into adenosine [12, 17].

Reader

In addition, another essential group of regulators of m6A modification is “reader”, which can recognize and bind to m6A methylated targets to induce various biological phenotypes. The “reader” mainly consists of YTH domain family of proteins (YTHDC1/2, YTHDF1/2/3) [49–55], IGF2 mRNA binding protein (IGF2BP1/2/3) [56–59], the heterokaryotic nuclear RNA protein family (HNRNPC, HNRNPG) [60–62], and eukaryotic initiation factor 3 (eIF3) [63, 64], which affect m6A methylation by modulating RNA metabolism [16].

Function of m6A

“Writers”, “erasers” and “readers” work together to effectively catalyze, remove and recognize m6A methylation and establish a reversible and dynamic balance of m6A modification. mRNA, miRNAs, and long noncoding RNAs can all be regulated by m6A methylation, which controls RNA stability, decay, translation, splicing, transport, localization, and RNA–protein interactions (Fig. 1) [20, 65–67].

Splicing

m6A modification can modulate pre-mRNA splicing by interacting with different splicing factors. FTO preferentially binds adjacent to the alternative splicing exon and polyA sites, thus depresses recruitment of serine/arginine-rich splicing factor 2 (SRSF2) and induces exon 6 skipping [44, 68]. ALKBH5 can promote the phosphorylation of ASF/SF2, and the hyper-phosphorylated ASF/SF2 participates in splicing [46]. It has been reported that downregulation of m6A writers interfered splicing and gene expression [69, 70]. Also, loss of hnRNPC/hnRNPQ can change the splicing pattern in an m6A-dependent way [62].

Nuclear export

Previous studies confirmed that ALKBH5 could restrain nuclear export, determining the subcellular location of mRNAs. Mechanistically, ALKBH5 can reduced the hypo-phosphorylated form of ASF/SF2, which promotes mRNA export mediated by TAP-p15 complex [71]. YTHDC1 facilitates nuclear export by promoting the binding of RNA to nuclear RNA export factor 1 (NXF1) and export adaptor protein SRSF3 [72]. Fragile X mental retardation protein (FMRP), another reader, was identified to be indispensable in CRM1-mediated nuclear export [73].

Translation

METTL3 can regulate translation via different readers specifically recognizing m6A sites. It can also exert regulatory role independent on methyltransferase activity, by interacting with eIF3h to promote translation [74, 75]. Recently, METTL16 has also been confirmed to regulate translation in both methyltransferase activity-dependent and -independent manner [27]. Notably, YTHDF proteins play important roles in modulating translation. YTHDF1 can promote the cap-dependent translation initiation by participating in the formation of loop structure with eIF4G and eIF3 and recruitment of ribosomes [49]. Besides, YTHDF1 can facilitate the expression of eIF3C in an m6A-dependent way [76]. In synergism with YTHDF1, YTHDF3 promotes translation via interacting with 40S and 60S ribosome subunits [77]. YTHDF3 also improves the translation efficiency of ITGA6 and promotes malignant progression of bladder cancer [78]. YTHDC2 can boost translation with its helicase activity, independent on m6A modification, which is enhanced by 5‘→3’ exoribonuclease XRN1 [79].

Stability

m6A modification serves as a double-edged sword in regulating mRNA stability. YTHDF2 plays a vital role in RNA degradation by recruiting the deadenylase complex CCR4-NOT [80]. And YTHDF3 cooperates with YTHDF2 to facilitate mRNA degradation [81]. For instance, YTHDF2 recognizes the methylation of suppressor of cytokine signaling 2 (SOCS2) and arrestin domain-containing protein 4 (ARRDC4) and induces their mRNA degradation thus enhances metastasis and dissemination of cancer cells [82, 83]. YTHDF1 can induce the degradation of MAT2A mRNA by binding to m6A sites in the 3'-UTR [84]. Another group of readers, IGF2BP1/2/3 can enhance mRNAs stability via KH domain binding to target m6A sites [56]. Moreover, FTO is reported to increase the stability of MYC mRNA by depressing the YTHDF2-mediated decay [85].

METTL14

As a key allosteric activator of METTL3, METTL14 functions as the major m6A methyltransferase to regulate m6A modification on mRNA and non-coding RNA. Advances have been achieved in exploring the crucial roles and molecular mechanisms of METTL14 in multipie types of cancer, especially in gastrointestinal cancer,
including liver cancer, colorectal cancer, gastric cancer, and pancreatic cancer. In this review, we will summarize the biological functions and underlying mechanisms of METTL14 in gastrointestinal cancer determined by the latest research progresses of our and other research teams, discuss the potential clinical applications and propose future research directions of METTL14 in gastrointestinal cancer.

The structural basis of METTL14
METTL3 and METTL14 form a stable heterodimer in 1:1 ratio, the N-terminal extension of METTL14 interacts with METTL3 via loops and helixes (Fig. 1) [32, 33]. METTL14 has the homologous methyltransferases domain (MTD) as METTL3, but it owns a closed conformation of catalytic chamber without SAM binding sites. And METTL14 lacks the two CYS-CYS-HIS (CCCH)-type zinc binding motifs of METTL3, which also deprives its catalytic activity [33]. However, it exerts an essential structural role to support METTL3’s catalytic function and METTL3 alone merely exhibits weak activity. Significantly, METTL14 provides an RNA-binding scaffold that plays a crucial role in recognizing and binding substrate RNAs [86]. The RGG repeats of the METTL14 C-terminus are supposed to contribute to the recognition of RNAs [87]. Similar to METTL3, METTL14 preferentially recognizes RNA with the “RRACH” (R=A/G, H=A/U/C) sequences [30], but the priority mechanism remains unclear.

The function role of METTL14 in gastrointestinal cancer
Recent researches have demonstrated that dysregulation of METTL14 is tightly relative to the phenotypes involved in the malignant development of various cancer, including proliferation [88–90], metastasis [91–96], apoptosis [97–101], drug resistance [102–105], cancer stem cell like characteristic [106, 107], immunotherapy [21, 108, 109], chronic inflammation [110] and glycolipid metabolism (Fig. 2) [95]. Herein, we systematically summarize the recent advances of METTL14 in gastrointestinal cancer (Table 1).

Liver cancer
Liver cancer (LC) is a common malignancy with the fourth lethality in cancers worldwide. The predominant form of LC is hepatocellular carcinoma (HCC), which accounts for ~ 80% of primary LC and present an increasing incidence globally [124]. Emerging reports have confirmed the significance of m6A modification in LC, and continuous efforts have been put to investigate...
the complicated molecular mechanism of abnormal m6A modification and dysregulation of m6A regulators in HCC. First of all, the expression level of METTL14 was identified to be obviously decreased in HCC, which closely correlated with clinicopathological factors, including tumor stage and prognosis (Fig. 3) [125–128]. Based on the analysis of data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO), Liu et al. showed the opposite expression level and prognostic value of METTL14 and METTL3 in HCC [127]. Similarly, METTL14 was predicted to participate in HCC malignant progression by modulating the m6A-modified transcripts, such as cysteine sulfonate decarboxylase (CSAD), glutamic oxalacetic transaminase (GOT2), and SOCS2 [126]. Through overlapping RNA-sequencing and m6A-sequencing data, epidermal growth factor receptor (EGFR) was identified as the direct target of METTL14. Knockdown of METTL14 activates EGFR/PI3K/AKT signaling and thus promotes epithelial-mesenchymal transition (EMT), migration and invasion of HCC cells [111]. In metastatic HCC, METTL14 interacts with the microprocessor protein DiGeorge syndrome critical region 8 (DGCR8) to suppress tumor metastasis. Mechanistically, METTL14 enhances the engagement of pri-miR126 by DGCR8 and promotes the subsequent processing into miRNA126, which was recognized as a metastasis suppressor. What's more, the researchers verified the suppressive role of miR126 in

| Cancer type | Role | Target | Upstream | Reader | Functions |
|-------------|------|--------|----------|--------|-----------|
| HCC         | Tumor suppressor | EGFR, PI3K/AKT | mTet14 | YTHDF2 | Suppresses migration and invasion [111] |
|             | Tumor suppressor | miR-126 |          |        | Suppresses metastasis [92] |
|             | Tumor suppressor | SLC7A11 | HIF-1α   | YTHDF2 | Suppresses hypoxia blocked-ferroptosis [112] |
|             | Tumor suppressor | USP48   | SIRT6    |        | Attenuates glycolysis and malignancy [113] |
|             | Oncogene | HNF3y   | ALCY     | SCID1  | Suppresses proliferation and sorafenib resistance [103] |
|             |         |         |          |        | Promotes FA synthesis and lipid accumulation [114] |
| CRC         | Tumor suppressor | miR-375 | YAP1/SP1 |        | Suppresses migration, invasion, proliferation [94] |
|             | Tumor suppressor | KLF4    |          |        |          |
|             | Tumor suppressor | ARRD4C4 | HuR, TCF4| YTHDF2 | Suppresses migration and invasion [115] |
|             | Tumor suppressor | SOX4    | KDM5C, H3K4me3 | YTHDF2 | Suppresses metastasis [116] |
|             | Tumor suppressor | LncR XIST |        | YTHDF2 | Suppresses proliferation and metastasis [93] |
|             | Tumor suppressor | miR-149-3p |        |        | Suppresses inflammation and malignancy [110] |
|             | Tumor suppressor | IFN-c/-STAT/IRF1 |        | YTHDF2 | Promotes immune responses to anti-PD-1 therapy [108] |
|             | Tumor suppressor | EB13    |          |        | Promotes antitumor response and CD8+ T cell infiltration [109] |
|             | Oncogene | ANKLE1 | YTHDF1 |        | Suppresses proliferation, and colony formation [117] |
| GC          | Tumor suppressor | circORC5 |          |        | Promotes Cetuximab Resistance [105] |
|             | Tumor suppressor | Wnt/Pi3K-Akt |        |        | Suppresses proliferation and invasion [118] |
|             | Tumor suppressor | Pi3K/AKT/mTOR |        |        | Suppresses proliferation and invasion [119] |
|             | Oncogene | LINC01320 |          |        | Suppresses proliferation and invasion [120] |
| PC          | Oncogene | PERP    |          |        | Promotes migration, invasion, proliferation [121] |
|             | Oncogene | CDA     | P65      |        | Suppresses growth and metastasis [91] |
|             | Oncogene | AMPKa/ERK/mTOR |        |        | Promotes gemcitabine resistance [122] |
|             | Oncogene | CLK1    | SRSF5    | YTHDF2 | Suppresses apoptosis and autophagy [101] |
|             | Tumor suppressor | PIK3CB  |          | YTHDF2 | Suppresses proliferation and invasion [123] |
|             | Tumor suppressor | LINC01320 |          |        | Suppresses proliferation and metastasis [96] |
HCC cell metastasis using miR126 mimic and inhibitor [92]. Beyond inhibiting metastasis, METTL14 serves as a tumor suppressor involved in various biological processes. METTL14 facilitates hypoxia-blocked ferroptosis of HCC cells by catalyzing m6A modification at the mRNA 5'UTR of solute carrier family 7 member 11 (SLC7A11), then promotes YTHDF2-dependent degradation of SCL7A11 transcripts [112]. METTL14-triggered m6A methylation also inhibits the degradation of ubiquitin specific peptidase 48 (USP48) mRNA, which can deubiquitylate and stabilize sirtuin 6 (SIRT6) to suppresses glycolysis and HCC tumorigenesis. The METTL14-USP48-SIRT6 signaling may be a potential therapeutic strategy for HCC in the future [113]. In addition, reduced METTL14 level in HCCs decreases the stability of m6A-modified hepatocyte nuclear factor-3γ (HNF-3γ) mRNA,
since decreased m6A level impairs IGF2BPs-mediated stabilization of mRNA. Reduced HNF3γ expression not only leads to HCC proliferation by inhibiting the differentiation of HCC cells and liver cancer stem cells, but also downregulates organic anion-transporting polypeptide 1B1 (OATP1B1) and 1B3 (OATP1B3) expression and thus impedes sorafenib uptake, resulting in the decreased sensitivity of HCC cells to sorafenib [103]. However, Yang et al. proposed the opposite role of METTL14 in HCC, they detected upregulated level of METTL14 in both HCC cells and patient samples. It was demonstrated that overexpressed METTL14 stabilized m6A-modified ATP citrate lyase (ACLY) and stearoyl-CoA desaturase 1 (SCD1) mRNA to increase their expression, thereafter aggravated FA damage and lipid accumulation, which contributed to DNA damage, chronic inflammation, cell apoptosis, excessive compensatory cell proliferation in livers, further developing non-alcohol fatty liver disease (NAFLD) and HCC [114]. In conclusion, these findings suggested the important impact of METTL14 on LC.

Colorectal cancer
Colorectal cancer (CRC) is a malignant tumor worldwide with an increasingly high incidence and mortality. Recurrence and metastasis are stubbornly major barriers to the treatment of CRC patients. According to the statistics, there are approximately 945,000 new cases and about 700,000 deaths of CRC every year [129–131]. Despite the great research advances in CRC over the years, the molecular mechanisms underlying tumorigenesis and development are still elusive. Recently, growing evidences revealed that METTL14-mediated m6A modification plays a vital role in controlling the progression of CRC (Fig. 3). Experimental studies and bioinformatics confirmed that METTL14 is highly expressed in CRC compared with normal tissues, and high expression level of METTL14 is closely associated with the better prognosis of CRC patients [83, 132, 133]. METTL14 can inhibit CRC metastasis and proliferation through multiple pathways and mechanisms. For example, Chen et al. discovered that the overexpressed METTL14 dramatically enhanced m6A level of CRC cells and suppressed CRC proliferation and metastasis in vitro, while METTL14 loss exerts opposite roles. Mechanistically, METTL14 modulates the processing of pre-miR-375 by DGCR8 and increases miR-375 level via a m6A dependent manner, which subsequently inhibits CRC growth and metastatic capability through downregulating Yes-associated protein 1 (YAP1) and SP1 respectively [94]. Wang et al. found that METTL14 can upregulate the expression of tumor suppressor protein Kruppel-like factor 4 (KLF4) to inhibit the invasion and metastasis of CRC cells. During this process, IGFBP2 was involved in identifying m6A methylation sites of KLF4 to stabilize its mRNA [115]. In addition, our recent study demonstrated that METTL14 served as an independent predictor of CRC survival and suppressed CRC metastasis in vivo and in vitro. Through转录组学sequencing (RNA-seq) and methylated RNA immunoprecipitation sequencing (MeRIP-seq), METTL14 was identified to down-regulate ARRDC4 by promoting its mRNA degradation depending on YTHDF2 recognition. Furthermore, the EMT related transcriptional factor ZEB1 was elevated by increased ARRDC4 in METTL14 deficient CRC cells, promoting metastasis of CRC [83]. Chen et al. also indicated METTL14 as a prognostic factor in CRC. They proved that METTL14 and YTHDF2 synergistically regulated m6A methylation modification and decreased the expression of SRY-box transcription factor 4 (SOX4), thereby abrogated EMT and PI3K/AKT signaling pathway, ultimately inhibited migration, invasion, and metastasis of CRC both in vivo and on vitro [116]. Another research confirmed that METTL14 blocked the metastasis and proliferation of CRC by decreasing oncogenic lncRNA XIST expression relying on YTHDF2-mediated degradation [93]. Recently, Tian et al. showed that the variant rs8100241[A] of tumor suppressor ankyrin repeat domain-containing protein 1 (Ankle1) could be more efficiently catalyzed by METTL14 and recognized by YTHDF1, thus upregulating m6A methylation level and protein expression of ANKLE1, which correlates with a reduced risk of CRC by suppressing tumor malignant proliferation and maintaining the genomic stability [117]. Moreover, besides metastasis and proliferation, METTL14 can modulate other malignant phenotypes. Dong et al. proved that METTL14 depletion in CRC-associated macrophages can induce Epstein-Barr virus induced 3 (EBI3) upregulation in an m6A dependent manner mediated by YTHDF2, contributing to CD8+ T cells dysfunction, thereafter accelerating malignant progression of CRC, which was verified by mouse models and clinical samples [109]. Nevertheless, Wang et al. observed that loss of METTL14 elevated the response of CRC to programmed cell death-1 (PD-1) therapy. Reduced METTL14 can promote the amount of CD8+ T cells to secrete interferon-γ (IFN-γ), Chemokine (C-X-C motif) ligand 19 (CXCL19) and CXCL10, via enhancing the stability of Signal transducer and activator of transcription 1 (STAT1) and interferon regulatory factor 1 (IRF1) mRNA dependent on YTHDF2, both of which are involved in IFN-γ signaling and anti-PD1 response. This enlightened that METTL14 could be a potential therapeutic target in mismatch-repair-proficient or microsatellite instability-low (pMMR-MSI-L) CRC [108]. Furthermore, Cao et al. revealed that Enterotoxigenic Bacteroides fragilis (ETBF) inhibited METTL14 to reduce...
m6A modified splicing of pri-miR-149, leading to down-regulation of miR-149-3p. Subsequently, the decreased miR-149-3p not only induced PHF5A-mediated KAT2A RNA alternative splicing to promote tumorigenesis of CRC, but also contributed to the differentiation of Th17 cells resulting in intestinal inflammation [110]. However, Luo et al. showed the proto-oncogene role of METTL14 in CRC. They found that oxidative stress induced by chemotherapeutic drug could upregulate METTL14, which elevated the expression of Pleckstrin homology-like domain family B member 2 (PHLDB2). Increased PHLDB2 enhanced EGFR stability, contributing to chemoresistance of CRC to cetuximab [105]. In summary, these studies proved the close connection between METTL14 and CRC progression, suggesting that METTL14 may be a potential therapeutic target for CRC treatment.

**Gastric cancer**

Gastric cancer (GC) is a common malignant tumor worldwide. Although the incidence and mortality of GC display a downward trend in recent years, there are a mass of GC patients in China with the third mortality rate in cancer death, remarkably higher than other countries and regions [134–137]. The fact that epigenetics plays a significant role in GC progression has been widely confirmed. However, the clinicopathological functions and molecular mechanisms of m6A modification in GC remain largely unclear. To date, there has been no consensus on the role of METTL14 in GC (Fig. 3). Fan et al. showed that METTL14 was downregulated in GC tissues and associated with the poor survival in GC patients. METTL14 deficiency induced proliferation and metastasis of GC cells both in vivo and in vitro, while METTL14 overexpression harbored the opposite roles. Mechanistically, METTL14 triggered circORC5 m6A methylation modification to repress its expression, thus increased miR-30c-2-3p expression and whereby downregulated AKT1 substrate 1 (AKT1S1) and eukaryotic translation initiation factor 4B (eIF4B), resulting in inhibition of GC tumorigenesis [118]. Liu et al. demonstrated that METTL14 was a tumor suppressor and potential biomarker of GC via bioinformatics analysis and clinical samples. METTL14 was downregulated in GC and exogenous expressed METTL14 repressed aggressive phenotype of GC by deactivating the PI3K/AKT/mTOR signaling axis [120]. In addition, Zhang et al. revealed that deficiency of METTL14 induced proliferation and invasion of GC cells by activating Wnt and PI3K-Akt signal pathway in vitro. And they also found the potential correlation between m6A level and immunotherapy features and interferon signaling in METTL14-knockdown cells [119]. Nevertheless, Hu et al. expressed the opposite view that METTL14-mediated upregulation of long noncoding RNA Linc01320 can facilitate GC tumorigenesis in vitro. Linc01320 was found to downregulate miR-495-5p, leading to upregulated RAB19 in GC cells, which promotes GC cells proliferation, migration, and invasion in an unclear mechanism [121]. Conclusively, the biofunctions and regulation mechanisms of METTL14 in GC are rarely investigated and the research advances are limited. It is worth to extensively explore the value of METTL14 in GC in the future research.

**Pancreatic cancer**

Pancreatic cancer (PC) is one of the most malignant tumors with a five-year survival rate of only 8% and largely PC patients die within seven years after surgery treatment [138, 139]. Since the mortality rates are on the rise, PC is predicted to become the second most common cause of cancer death by 2030 [140]. However, the underlying mechanisms of PC’s high lethality are still not well determined. Therefore, screening and identifying the critical molecules that regulate PC progression is meaningful for performing possible therapeutic strategies. Recently, emerging studies have reported the important role of m6A modification in PC (Fig. 3). Bioinformatics projections showed that the expression of METTL14 was closely related to overall survival of pancreatic ductal adenocarcinoma (PDAC) [141]. Based on TCGA database, Xu et al. established an independent risk prognostic signature of PC consisted of 5 m6A regulating genes, including METTL14, METTL3, KIAA1429, ALKBH5 and YTHDF1 [142]. Wang et al. determined that METTL14 served as an oncogene in PC. METTL14 was highly expressed in PC tissue and associated with the poor survival of PC patients. Increased METTL14 expression induced the degradation of p53 effector related to PMP-22 (PERP) via m6A dependent manner, contributing to the proliferation and metastasis of PC [91]. Interestingly, Chen et al. found that Cdc2-like kinases 1 (CLK1)/SR-like splicing factors5 (SRSF5) axis mediated aberrant exon skipping of METTL14, which leads to dysregulated m6A methylation modification and promotes the proliferation and metastasis of PDAC [96]. Moreover, Tian et al. showed that the variant rs142933486[G] allele of oncogene phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta (PIK3CB) was correlated with high level of m6A modification, which was catalyzed by METTL14 and recognized by YTHDF2. This could promote mRNA decay and decrease PIK3CB expression, leading to a reduced risk of PC [123]. A recent study showed that the expression of METTL14 was increased in gemcitabine resistant PC cells, while inhibition of METTL14 significantly enhanced the gemcitabine sensitivity of resistant PC cells by downregulating cytidine...
deaminase (CDA), an enzyme which can inactivate gemcitabine. And the downregulation of CDA is supposed to be mediated by regulation on the mRNA stability in an m6A-dependent manner [122]. Similarly, METTL14 knockdown promoted apoptosis and autophagy and enhanced sensibility of PC cells to cisplatin by repressing AMPKα, ERK1/2 and mTOR signal pathways, but the regulatory mechanisms of METTL14 and the exact roles of AMPKα and ERK1/2 in this process need further explorations [101]. In general, the role of METTL14 in PC is distinct from that in HCC, CRC, and GC. Since METTL14 acts as an oncogene in PC, it may be an effective therapeutic target for PC.

Upstream regulators of METTL14
Considering the important role of METTL14 in cancer progression, emerging studies have pay emphasis on the upstream regulatory mechanisms involved in the aberrant expression of METTL14 in cancer (Fig. 4).

Transcriptional regulation
It was universally recognized that transcriptional factors and histone modification play the key role in regulating METTL14. In bladder cancer cells, knockdown of transcriptional factor forkhead box O3a (FOXO3a) conspicuously decreased METTL14 expression [143]. A recent study revealed that the transcriptional factor p65 was involved in upregulating METTL14 by targeting its promoter site in PC cells [122]. Moreover, Weng et al. showed that transcription factor PU.1 (Putative oncogene Spi-1, SPI1) functioned as a direct transcriptional suppressor of METTL14. SPI1 knockdown led to upregulation of METTL14 mRNA and protein in both normal and malignant hematopoietic cells, while SPI1 overexpression harbored the opposite effect in these cells [107]. In CRC, our latest findings proved that RNA-binding protein human antigen R (HuR) directly bound to METTL14 promoter and thus suppressed its expression [83]. In addition, Chen et al. indicated that (K)-specific demethylase 5C (KDM5C)-mediated demethylation of H3K4me3 could repress the transcription of METTL14 [116].

Posttranscriptional regulation
Chen et al. found that CLK1/SRSF5 axis could regulate aberrant exon skipping of METTL14 [96]. Through transcriptome sequencing, METTL14 exon10 skipping regulated by the CLK1-SRSF5 axis was identified as the key alternative splicing event, promoting the m6A modification level and metastasis of PDAC cells.

Posttranslational regulation
Recently, we demonstrated that transcriptional factor 4 (TCF4) depletion downregulated METTL14 expression via promoting its ubiquitination-mediated degradation in CRC. Furthermore, Wei et al. revealed that endoplasmic reticulum (ER) proteotoxic stress selectively promoted METTL14 expression through inhibiting its ubiquitination-mediated degradation by repressing HMG-CoA reductase degradation protein 1 (HRD1), an important E3 ubiquitin ligase of METTL14 [100].

Taken together, these findings illustrate that METTL14 abnormal expression can be affected by a series of transcription factors, histone modification and ubiquitination-mediated degradation. Investigation on the upstream regulatory mechanisms of METTL14 dysregulation helps us to better comprehend the biological role of METTL14 in cancers and provides possible therapeutic targets for anti-tumor therapy.

Potential clinical application of METTL14
The above evidences emphasize that METTL14 is essential for tumorigenesis and development of gastrointestinal cancer, suggesting that METTL14 may be a promising biomarker for clinical diagnosis and potential therapeutic target of gastrointestinal cancer. The results from our and other laboratories showed that METTL14 was downregulated in CRC, HCC and GC, repressed tumor proliferation and metastasis and correlated negatively with tumor prognosis [83, 92, 93, 116, 118]. And we found that decreased METTL14 level was tightly associated with tumor stages of CRC. By the multivariate Cox regression analysis, METTL14 was identified as an independent prognostic factor for CRC patients [83]. Therefore, METTL14 may be a promising biomarker of aggressive CRC, HCC, and GC. However, it is obvious that more attention has been paid on exploring the functions and mechanisms of METTL14 in gastrointestinal cancer, while the expression of METTL14 in early stage of tumorigenesis need to be further investigated and confirmed. It is worthwhile to evaluate METTL14 as a biomarker for early diagnosis and prevention of gastrointestinal cancer in the future studies.

Immunotherapy has become one of the unprecedented therapeutic strategies for multiple malignant tumors by modulating the immune system of cancer patients. By targeting m6A modification, immune responses can be further significantly activated during antitumor immunotherapy. A recent study indicated that suppression of METTL14 mediated-m6A mRNA modification elevated the therapeutic effect of anti-PD-1 therapy in CRC. Inhibition of METTL14 not only promoted the proliferation and accumulation of cytotoxic tumor-infiltrating
CD8+ T cells, but also induced the secretion of IFN-C, CXCL9, and CXCL10, thus enhanced immunotherapy efficacy and suppressed cancer proliferation [108]. In addition, METTL14 plays an important role in regulating chemoresistance, which seriously limited the efficacy of chemotherapy, the main clinical treatment for gastrointestinal cancer. In PC, METTL14 knockdown enhanced sensibility of cancer cells to cisplatin,
promoting apoptosis and autophagy by repressing AMPKα, ERK1/2 and mTOR signal pathways [101]. Similarly, inhibition of METTL14 enhanced the gemcitabine sensitivity of PC cells by downregulating CDA [122]. METTL14 also mediated chemoresistance of CRC cells to cetuximab and HCC cell to sorafenib [103]. Given the crucial role of METTL14 in gastrointestinal cancer, it is urgently expected to screen, design, and develop effective METTL14 inhibitors and activators. Additionally, exploring drugs targeting upstream or downstream molecules of METTL14 may also be an effective measure for gastrointestinal cancer therapy. The combined applications of METTL14 inhibitor or activators with chemotherapy or immunotherapy show great potential as a promising treatment strategy and are anticipated to be investigated in the future.

**Discussion**

m6A methylation is the most abundant RNA modification and has become research hotspot in recent years. m6A methylation affects the processing of mRNA and non-coding RNA and is of great significance for gene expression regulation. Mounting evidence indicated that m6A modification plays a critical role in tumorigenesis and progression. The present review showed the expression, function, and the regulatory mechanism of the methyltransferase METTL14 in gastrointestinal cancer, suggesting that METTL14 might be a promising biomarker for clinical diagnosis and therapeutic target of gastrointestinal cancer. However, with breakthroughs made in various aspects, contradictions and uncertainties have also been exposed, which is mainly consist of the following situations. (1) In different cancers, METTL14 has a dual regulatory effect on tumors. It serves as an oncogene in PC, while plays a suppressive role in HCC, CRC, and GC. Such complexity highlights that attention should be given to the application of METTL14 activators or inhibitors in case of inducing other tumors. (2) In different cancers, the expression level of METTL14 varies a lot. Some upstream regulations have been identified in specific cellular context, at transcriptional, posttranscriptional, and posttranslational level. However, the underlying rationales of whether it is upregulated or downregulated remain elusive. (3) For the same cancer, different researchers hold the opposite conclusions of METTL14. For example, Fan et al. found that overexpressed METTL14 inhibited proliferation and metastasis of GC [118], but Hu and his colleagues proved that METTL14-mediated upregulation of Linc01320 promotes GC cells proliferation, metastasis [121]. (4) For the same cancer, different studies showed the inconsistent results of METTL14. For instance, Dong et al. showed that inhibition of METTL14 resulted in CD8+ T cells dysfunction and promoted malignant progression of CRC [109]. Nevertheless, Wang et al. indicated that METTL14 deletion enhanced the efficiency of CD8+ T cells and elevated the immune response of CRC [108]. To sum up, multi-center large-scale studies are extremely required to further determine the role of METTL14 in gastrointestinal cancer, which could lay a foundation for precise individualized treatment.

Although great advances have been achieved in revealing the functions and regulatory mechanisms of METTL14, some problems need to be further explored. (1) As an integrity of m6A methyltransferase complex, METTL14 and METTL3 are supposed to have synergistic effects. However, many findings have demonstrated the opposite expression and functions between them in various cancers. Also, different targets and regulatory mechanisms of METTL3 and METTL14 have been proved. We hypothesized that they have biological functions independent of the methyltransferase complex, with their own bias towards targets. Therefore, the structural basis and regulatory roles of the METTL3/14 complex, and their respective functional mechanisms require further experimental verification. (2) As a promising biomarker for tumor clinical diagnosis, the sensitivity and specificity of METTL14 need to be further clarified. (3) Previous studies suggested that METTL14 may be a potential therapeutic target for gastrointestinal cancer, but insufficient attention was paid to drug development and no specific chemotherapeutic agent targeting METTL14 has been reported in both experimental researches and clinical practice so far. It is worth to determine the validity and feasibility of METTL14-targeted agents alone or in combination with existing therapies for treating tumors in the future. Importantly, special emphasis shall be given on the development of METTL14 inhibitors or activators in cancer treatment due to the double-edged sword roles of METTL14 in gastrointestinal cancer.

**Conclusion**

In summary, METTL14 plays an important role in gastrointestinal cancer and it may serve as a promising diagnostic/prognostic biomarker and a potential therapeutic target. We anticipate more future researches to further explore the therapeutic potential of METTL14 for feasible application in clinical practice.

**Abbreviations**

3'UTRs: 3’ untranslated regions; ACLY: ATP citrate lyase; ALKBH3/5: AlkB homolog 3/5 RNA demethylase; Ankle1: Ankyrin repeat and LEM domain-containing protein 1; AKT1S1: AKT1 substrate 1; ARRDC4: Arrestin domain-containing protein 4; CLK1: Cdc2-like kinases 1; CRC: Colorectal cancer; CSAD: Cysteine sulfonate decarboxylase; CXCL19: Chemokine (C-X-C motif) ligand 19; DGCR8: DiGeorge syndrome critical region 8; EB13: Epstein-Barr virus induced 3; EGFR: Epidermal growth factor receptor; elfF: Eukaryotic initiation
factor; EMT: Epithelial-mesenchymal transition; ER: Endoplasmic reticulum; Flacc: Fl(2)d-associated complex component; FOXO3a: Forkhead box O3a; FTO: Fat mass and obesity-associated protein; GC: Gastric cancer; GEO: Gene Expression Omnibus; GNF: Glutamine oxaloacetate transaminase; HCC: Hepatocellular carcinoma; HNF-3γ: Hepatocyte nuclear factor-3γ; HNRNP: Heterokaryotic nuclear RNA protein; HRD1: HMG-CoA reductase degradation protein 1; HuR: Human antigen R; IFN-c: Interferon-c; IGF2BP: IGF2 mRNA binding protein; KDMSC: (K)-specific demethylase SC; LC: Liver cancer; m1G: 1-Methylguanosine; m5C: 5-Methylcytosine; m6A: N6-methyladenosine; METTL3/14/16: Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta; RBM15/15B: RNA-binding motif protein 15/15B; SCD1: Stearoyl-CoA desaturase 1; SIRT6: Sirtuin 6; SLC7A11: Solute carrier family 7 member 11; SOCS2: Suppressor of cytokine signaling 2; SOX4: SRY-box transcription factor 4; Sp1: Sp1 transcription factor PUL1; SRSF5: SR-like splicing factors 5; TCF4: Transcription factor 4; TGGA: The Cancer Genome Atlas; USP48: Ubiquitin specific peptidase 48; VIRMA/XIAA.1429: Virlike m6A methyltransferase-associated; WTAP: WT1-associated protein; YTHD: YTH domain family of protein; ZC3H13: Zinc finger CCCH-type containing 13.

Acknowledgements
Not applicable.

Authors’ contributions
Bin Shi and Ke Yang collected the related literature. Hao Wang, Ke Yang and Bin Shi wrote the manuscript. Wei-Wei Liu revised the manuscript. Hao Wang and Guan-min Jiang participated in the design of the review and revised the manuscript. All authors have read and approved the final manuscript.

Funding
This study was supported by the Youth Innovation Project of University of Science and Technology of China (WK20110000203), the Natural Science Foundation of Anhui Province (2008085M2341), the National Natural Science Foundation of China (No. 82072365) and Guangdong Basic and Applied Basic Research Foundation (No. 2019A1515011666).

Availability of data and materials
Not Applicable.

Declarations
Ethics approval and consent to participate
Not Applicable.

Consent for publication
Not Applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Anorectal Surgery, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China. 2School of Basic Medical Sciences, Shandong University, Jinan, China. 3School of Clinical Medicine, Clinical College of Anhui Medical University, Hefei, China. 4Department of Clinical Laboratory, The Fifth Affiliated Hospital, Sun Yat-Sen University, Zhuhai, China. 5Department of Clinical Laboratory, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China. 6Core Unit of National Clinical Research Center for Laboratory Medicine, Hefei, China.

Received: 16 June 2022   Accepted: 8 August 2022

References
1. Li S, Kuo HD, Yin R, Wu R, Liu X, Wang L, Hudlikar R, Peter RM, Kong AN. Epigenetics/epigenomics of triterpenoids in cancer prevention and in health. Biochem Pharmacol. 2020;175: 113890.
2. Lin YT, Wu KJ. Epigenetic regulation of epithelial-mesenchymal transition: focusing on hypoxia and TGF-beta signaling. J Biomed Sci. 2020;27:39.
3. Zhou S, Treloar AE, Lupen M. Emergence of the Noncoding Cancer Genome: A Target of Genetic and Epigenetic Alterations. Cancer Discov. 2016;6:1215–29.
4. Chiba T, Matushava H, Ushijima T. Inflammation-associated cancer development in digestive organs: mechanisms and roles for genetic and epigenetic modulation. Gastroenterology. 2012;143:550–63.
5. Hu BB, Wang XY, Gu XY, Zou C, Gao ZJ, Zhang H, Fan Y. N6-methyladenosine (m6A) RNA modification in gastrointestinal tract cancers: roles, mechanisms, and applications. Mol Cancer. 2019;18:178.
6. Nebiobisa A, Tamboro FP, Dell’Aversana C, Altucci L. Cancer epigenetics: Moving forward. PLoS Genet. 2018;14:e1007362.
7. Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell. 2012;150:12–27.
8. Kelly AD, Issa JJ. The promise of epigenetic therapy: reprogramming the cancer epigenome. Curr Opin Genet Dev. 2017;42:68–77.
9. Traube FR, Carell T. The chemistries and consequences of DNA and RNA methylation and demethylation. RNA Biol. 2017;14:1099–107.
10. Zhao BS, Roundtree IA, He C. Post-transcriptional gene regulation by mRNA modifications. Nat Rev Mol Cell Biol. 2017;18:31–42.
11. He PC, He C, m(6)A RNA methylation: from mechanisms to therapeutic potential. Embo J. 2021;40:e105977.
12. Guan Q, Lin H, Miao L, Guo H, Chen Y, Zhuo Z, He J. Functions, mechanisms, and therapeutic implications of METTL14 in human cancer. J Hematol Oncol. 2022;15:1.
13. Zhang Y, Geng X, Li Q, Xu J, Tan Y, Xiao M, Song J, Liu F, Fang C, Wang H. m6A modification in RNA: biogenesis, functions and roles in gliomas. J Exp Clin Cancer Res. 2020;39:192.
14. He L, Li H, Wu A, Peng Y, Shu G, Yin G. Functions of N6-methyladenosine and its role in cancer. Mol Cancer. 2019;18:176.
15. Li J, Liang L, Yang Y, Li X, Ma Y. N(6)-methyladenosine as a biological and clinical determinant in colorectal cancer: progression and future direction. Theranostics. 2021;11:2581–93.
16. Jiang X, Liu B, Nie Z, Duan L, Xiong Q, Jin Z, Yang C, Chen Y. The role of m6A modification in the biological functions and diseases. Signal Transduct Target Ther. 2021;6:74.
17. Wang T, Kong S, Tao M, Ju S. The potential role of RNA N6-methyladenosine in Cancer progression. Mol Cancer. 2020;19:88.
18. Zhou Z, Lv J, Yu H, Han J, Yang X, Feng D, Wu Q, Yuan B, Lu Q, Yang H. Mechanism of RNA modification N6-methyladenosine in human cancer. Mol Cancer. 2020;19:104.
19. Zhu ZM, Huo FC, Pei DS. Function and evolution of RNA N6-methyladenosine modification. Int J Biol Sci. 2020;16:1929–40.
20. Dai DJ, Wang H, Zhu L, Jin H, Wang X. N6-methyladenosine links RNA metabolism to cancer progression. Cell Death Dis. 2018;9:124.
21. Lou X, Wang JJ, Wei YQ, Sun JJ. Emerging role of RNA modification N6-methyladenosine in immune evasion. Cell Death Dis. 2021;12:300.
22. Zaccara S, Ries JR, Jeffrey SR. Reading, writing and erasing mRNA methylation. Nat Rev Mol Cell Biol. 2019;20:608–26.
23. Guo T, Duan H, Chen J, Liu J, Othmane B, Hu J, Li H, Zhu N. N6-methyladenosine Writer Gene ZC3H13 Predicts Immune Phenotype and Therapeutic Opportunities in Kidney Renal Clear Cell Carcinoma. Front Oncol. 2021;11:718644.
24. Li T, Hu PS, Zuo Z, Lin JF, Li X, Wu QN, Chen ZH, Zeng ZL, Wang F, Zheng J, et al. METTL3 facilitates tumor progression via an m(6)A-dependent mechanism in colorectal carcinoma. Mol Cancer. 2019;18:112.
25. Xie S, Chen W, Chen K, Chang Y, Yang F, Lin A, Shu Q, Zhou T, Yan X. Emerging roles of RNA methylation in gastrointestinal cancers. Cancer Cell Int. 2020;20:585.
26. Lan Q, Liu PY, Haase J, Bell JL, Huttelaier S, Liu T. The Critical Role of RNA m6A Methylation in Cancer. Cancer Res. 2019;79:1285–92.
27. Su R, Dong L, Li Y, Gao M, He PC, Liu W, Wei J, Zhao Z, Gao L, Han L, et al. METTL16 exerts an m6A-dependent function to facilitate translation and tumorigenesis. Nat Cell Biol. 2022;24:205–16.
28. Ruszkowska A. METTL16, Methyltransferase-Like Protein 16: Current Insights into Structure and Function. Int J Mol Sci. 2021;22(4):2176.
29. Pendleton KE, Chen B, Liu K, Hunter OV, Xie Y, Tu BP, Conrad NK. The U6 snRNA m6A writer METTL16 regulates S phase reentry. Nature. 2017;550:824–35.
30. Liu J, Yue Y, Han D, Wang X, Fu Y, Zhang L, Jia G, Yu M, Lu Z, Deng X, et al. A METTL3-METTL14 complex mediates mammalian nuclear RNA N6-adenosine methylation. Nat Chem Biol. 2014;10:93–5.
31. Zeng C, Huang W, Li Y, Wang H. Roles of METTL3 in cancer: mechanisms and therapeutic targeting. J Hematol Oncol. 2020;13:17.
32. Wang X, Peng J, Yue X, Guan Z, Zhang D, Liu Z, Gong Z, Wang Q, Huang J, Tan C, et al. Structural basis of N(6)-adenosine methylation by the METTL3-METTL14 complex. Nature. 2016;534:574–8.
33. Wang P, Doxat KA, Nam Y. Structural Basis for Cooperative Function of Mettl3 and Mettl14 Methyltransferases. Mol Biol. 2016;63:306–17.
34. Ping XL, Sun BF, Wang L, Xiao W, Yang X, Wang W, Adhikari S, Shi Y, Lv Y, Chen YS, et al. Mammalian WTAP is a regulatory subunit of the RNA N6-methyladenosine methyltransferase. Cell Res. 2014;24:177–89.
35. Chen Y, Peng C, Chen J, Chen D, Yang B, He B, Hu W, Zhang Y, Liu H, Dai L, et al. WTAP facilitates progression of hepatocellular carcinoma via m6A-HuR-dependent epigenetic silencing of ETS1. Mol Cancer. 2019;18:127.
36. Chen S, Li Y, Zhi S, Ding Z, Wang W, Peng Y, Huang Y, Zheng R, Yu H, Wang J, et al. WTAP promotes osteosarcoma tumorigenesis by repressing HMOX1 expression in an m6A-dependent manner. Cell Death Dis. 2020;11:569.
37. Satterwhite ER, Mansfield KD. RNA methyltransferase METTL16: Targets and function. Wiley Interdiscip Rev RNA. 2022;13:e1681.
38. Mendel M, Chen KM, Homolka D, Gos P, Pandey RR, McCarthy AA, Pillai RS. Methylation of Structured RNA by the m(6)A Writer METTL16 Is Essential for Mouse Embryonic Development. Mol Cell. 2018;71:986–1000.
39. Warda AS, Kretschmer J, Hackert P, Lenz C, Urlaub H, Hobartner C, Sloan KE, Bohnsack MT. Human METTL16 is a N(6)-methyladenosine (m6A) methyltransferase that targets pre-mRNAs and various non-coding RNAs. Embo Rep. 2017;18:2004–14.
40. Wen J, Lu R, Ma H, Shen H, He C, Wang J, Jiao F, Liu H, Yang P, Tan L, et al. Zc3h13 Regulates Nuclear RNA m6A Methylation and Mouse Embryonic Stem Cell Self-Renewal. Mol Cell. 2018;69:1028–38.
41. Yue Y, Liu J, Cui X, Cao J, Luo G, Zeng Y, Teng G, Mao T, Shu X, Ma H, et al. VIRMA mediates preferential m(6)A mRNA methylation in 3'UTR and near stop codon and associates with alternative polyadenylation. Cell Discov. 2018;4:10.
42. Knuckles P, Lence T, Haussmann IU, Jacob D, Kreim N, Carl SH, Masiello I, Hares T, Villasenor R, Hess D, et al. Zc3h13/Fasc is required for adenosine methylation by bridging the mRNA-binding factor Rbm15/SnoN to the m6A RNA methyltransferase. Cell. 2018;172:415–29.
43. Liu C, Yuan CL, et al. Recognition of RNA N(6)-methyladenosine by YTHDC2 is an N(6)-methyladenosine binding protein that regulates mammalian spermatogenesis. Cell Res. 2017;27:1115–27.
44. Spenito to the m(6)A machinery component WTAP. Genes Dev. 2020;34:196–206.
45. Lu Z, Peng Y, Li J, Chen Z, Chen F, Tu J, Lin S, Wang H. N(6)-methyladenosine modification in coding and non-coding RNAs: Roles and Therapeutic Implications in Cancer. Cancer Cell. 2020;37:270–88.
46. Deng X, Su R, Peng W, Huang H, Li Z, Chen J. RNA N(6)-methyladenosine modification in cancers: current status and perspectives. Cell Res. 2018;28:507–17.
47. Bartosovic M, Molares HC, Gregorova P, Hrossova D, Kudla G, Vanacova I, Dominissini D, Moshitch-Moshkovitz S, Schwartz S, Salmon-Dixon M, Ungar L, Osenberg S, Csernansky J, Jacob-Hirsch J, Amariglio N, Kucpe M, et al. Topology of the human and mouse m6A RNA methylomes revealed by m6A-seq. Nature. 2012;485:201–6.
71. Li X, Manley JL. Inactivation of the SR protein splicing factor ASF/SF2 results in genomic instability. Cell. 2005;122:365–78.

72. Roundtree IA, Luo GZ, Zhang Z, Wang X, Zhou T, Cui Y, Sha J, Huang X, Guerrero L, Xie P, et al. YTHDC1 mediates nuclear export of N(6)-methyladenosine mRNA. Elife. 2017;6:e33111.

73. Edens BM, Vissers C, Su J, Arumugam S, Xu Z, Shi H, Miller N, Rojas RF, Ming GL, He C, et al. FMRP Modulates Neural Determination through m(6)A-Dependent mRNA Nuclear Export. Cell Rep. 2019;28:845–54.

74. Ianniello Z, Sorci M, Ceci GL, Iaiza A, Marchioni M, Tito C, Capuano E, Li A, Chen YS, Ping XL, Yang X, Xiao W, Yang Y, Sun HY, Zhu Q, Baidya Du H, Zhao Y, He J, Zhang Y, Xi H, Liu M, Ma J, Wu L. YTHDF2 destabilizes m(6)A-dependent and-independent roles of METTL3 in sustaining aberrant translation in chronic myeloid leukemia. Cell Death Dis. 2021;12:809.

75. Choje J, Lin S, Zhang W, Liu Q, Wang L, Ramirez-Moya J, Du P, Kim W, Tang S, Zhang P, et al. RNA circularization by METTL3-eIF3 enhances translation and promotes oncogenesis. Nature. 2018;561:556–60.

76. Liu T, Wei Q, Jin L, Luo Q, Liu Y, Yang L, Cheng C, Li L, Li J, Yi Y, et al. The m6A reader YTHDF1 promotes ovarian cancer progression via augmenting EFS3 translation. Nucleic Acids Res. 2020;48:3816–31.

77. Li A, Chen YS, Ping XL, Yang X, Xiao W, Yang Y, Sun HY, Zhu Q, Baidya P, Wang X, et al. Cytoplasmic m(6)A reader YTHDF3 promotes mRNA translation. Cell Res. 2017;27:444–7.

78. Jin H, Yang X, Que B, Wang X, Chao Y, Zhang H, Yuan Z, Qi D, Lin S, Min W, et al. N(6)-methyladenosine modification of tRNA6a mRNA promotes the development and progression of bladder cancer. EBioMedicine. 2019;47:195–207.

79. Li L, Krasnykov Y, Hormolka D, Gos P, Mendel M, Fish RJ, Pandey RR, Pillais A. The XRN1-regulated RNA helicase activity of YTHDC2 ensures mouse fertility independently of m6A recognition. Mol Cell. 2022;82:1678–90.

80. Du H, Zhao Y, He J, Zhang Y, Xi H, Liu M, Ma J, Wu L. YTHDF2 destabilizes m(6)A-containing RNA through direct recruitment of the CCR4-NOT deadenylase complex. Nat Commun. 2016;7:12626.

81. Shi H, Wang X, Lu Z, Zhao BS, Ma H, Hsu Pj, Liu C, He C, YTHDF3 facilitates translation and decay of N(6)-methyladenosine-modified RNA. Cell Res. 2017;27:315–28.

82. Chen M, Wei L, Law CT, Tsang FH, Shen J, Cheng CL, Tsang LH, Ho DW, Chiu DK, Lee JM, et al. RNA N6-methyladenosine methyltransferase-like 3 promotes liver cancer progression through YTHDC2-dependent post-transcriptional silencing of SOCS2. Hepatology. 2018;67:2254–70.

83. Wang H, Wei W, Zhang ZY, Liu Y, Shi B, Zhong W, Zhang HS, Fang X, Sun CL, Wang JB, Liu L. TCF4 and Hurl mediated-METTL14 suppresses dissemination of colorectal cancer via N6-methyladenosine-dependent silencing of ARRBDC4. Cell Death Dis. 2021;13:3.

84. Shima H, Matsumoto M, Ishigami Y, Ebina M, Muto A, Kumaqai S, Ochiai K, Suzuki I, Igarashi K. S-Adenosylmethionine Synthesis Is Regulated by Selective N6-Adenosine Methylation and mRNA Degradation Involving METTL16 and YTHDC1. Cell Rep. 2017;21:1353–64.

85. Su R, Dong L, Li C, Nacherlaga M, Wunderlich M, Qing Y, Deng X, Wang Y, Weng K, Hu C, et al. R-2HG Exhibits Anti-tumor Activity by Targeting FTO/m(6)A/MYC/CEBPA Signaling. Cell. 2018;172:90–105.

86. Kong F, Liu X, Zhou Y, Hou X, He J, Li Q, Mao X, Yang L. Downregulation of METTL14 increases apoptosis and autophagy induced by cisplatin in pancreatic cancer cells. Int J Biochem Cell Biol. 2020;122:105731.

87. Qiao X, Zhu L, Song R, Shang C, Guo Y. METTL3/4 and IL-17 signaling contribute to CEBPA-ET enhanced oral cancer cisplatin resistance. Oral Dis. 2021;27:1–15.

88. Zhou L, Xu W, Wu S, Wang X, Xie S, Wu T, Liu J, Dong C, Wang X, Zhou Y. A methyltransferase-like 14/m6A-99a-Sp/tribble 2 positive feedback circuit promotes cancer stem cell persistence and radiosensitivity via histone deacetylase-2-mediated epigenetic modulation in esophageal squamous cell carcinoma. Clin Transl Med. 2021;11:9.e545.

89. Wong H, Huang H, Wu H, Qin X, Zhao BS, Dong L, Shi H, Skibbon J, Shen C, Hu C, et al. METTL14 Inhibits Hematopoietic Stem/Progenitor Differentiation and Promotes Leukemogenesis via mRNA m(6)A Modification. Cell Stem Cell. 2018;22:191–205.

90. Wang L, Hui H, Agrama K, Kang Y, Li N, Tang R, Yuan J, Rana TM. m(6)A RNA methyltransferases METTL3/14 regulate immune responses to anti-PD-1 therapy. Embo J. 2020;39:e105414.

91. Dong L, Chen C, Zhang Y, Guo Z, Wang Z, Li J, Liu Y, Liu J, Chang R, Li Y, et al. The loss of RNA N(6)-adenosine methyltransferase Mettl4 in tumor-associated macrophages promotes CD8(+) T cell dysfunction and tumor growth. Cancer Cell. 2021;39:945–57.
110. Cao Y, Wang Z, Yan Y, Ji L, He J, Xuan B, Shen C, Ma Y, Jiang S, He J, et al. Shi et al. Molecular Cancer (2022) 21:163
111. Shi Y, Zhuang Y, Zhang J, Chen M, Wu S. METTL14 Inhibits Hepatocellular Carcinoma Metastasis Through Regulating EGFR/PI3K/AKT Signaling Pathway in an m6A-Dependent Manner. Cancer Manag Res. 2020;12:13173–84.
112. Fan Z, Yang G, Zhang W, Liu Q, Liu G, Liu P, Xu L, Wang J, Yan Z, Han H, et al. Hypoxia blocks ferroptosis of hepatocellular carcinoma via suppression of METTL14 triggered YTHDF2-dependent silencing of SLC7A11. J Cell Mol Med. 2021;25:10197–212.
113. Du L, Li Y, Kang M, Feng M, Ren Y, Dai H, Wang Y, Wang Y, Tang B. USP48 Is Upregulated by Mettl14 to Attenuate Hepatocellular Carcinoma via Regulating SIRT6 Stabilization. Cancer Res. 2021;81:3822–34.
114. Yang Y, Cai J, Yang X, Wang K, Sun K, Yang Z, Zhang L, Gu C, et al. Dysregulated m6A modification promotes lipogenesis and development of non-alcoholic fatty liver disease and hepatocellular carcinoma. Mol Ther. 2022;30(6):2342–53.
115. Wang S, Gan M, Chen C, Zhang Y, Kong J, Zhang H, Li M. Cell Proliferation of Tumor Cells in Colorectal Cancer Is Upregulated by Mettl14 to Attenuate Hepatocellular Carcinoma via Regulating EGFR/PI3K/AKT Pathway. Mol Cancer. 2021;20:81.
116. Chen X, Xu M, Xu X, Zeng K, Liu X, Pan B, Li C, Sun L, Qin J, Xu T, et al. METTL14-mediated N6-methyladenosine modification of SOX4 mRNA inhibits tumor metastasis in colorectal cancer. Mol Cancer. 2020;19:106.
117. Tian J, Ying P, Ke J, Zhu Y, Yang G, You D, Peng X, Yang N, Wang X, et al. ANKLE1 N6-methyladenosine-related variant is associated with colorectal cancer risk by maintaining the genomic stability. Int J Cancer. 2020;146:3281–93.
118. Fan HN, Chen ZY, Chen XY, Chen M, YiYC, Zhu JS, Zhang J. METTL14-mediated N6-methyladenosine methylation through methyltransferase-like 14. Cancer Sci. 2021;112:3243–54.
119. Zhang C, Zhang M, Ge S, Huang W, Lin X, Gao J, Gao J, Shen L, et al. Reduced m6A modification predicts malignant phenotypes and augmented Wnt/PI3K-AKT signalling in gastric cancer. Cancer Med. 2019;8:4766–81.
120. Liu X, Xiao M, Zhang L, Li L, Zhu G, Shen E, Lv M, Li X, Sun Z. The m6A methyltransferase METTL14 inhibits the proliferation, migration, and invasion of gastric cancer by regulating the PI3K/AKT/mTOR signaling pathway. J Clin Lab Anal. 2021;35: e263655.
121. Hu N, Ji H. N6-methyladenosine (m6A)-mediated up-regulation of long noncoding RNA LIN01320 promotes the proliferation, migration, and invasion of gastric cancer via miR495-5p/RAI19 axis. Bioengineered. 2021;12:4081–91.
122. Zhang C, Ou S, Zhou Y, Liu P, Zhang P, Li Z, Xu R, Li Y. m6A methyltransferase METTL14-mediated up-regulation of Cytidine Deaminase Promoting GEMCIN Methylation Resistance in Pancreatic Cancer. Front Cell Dev Biol. 2021;11:696371.
123. Tian J, Zhu Y, Cao M, Cai Y, Liu Z, Zou D, Peng X, Yang Z, Zhang H, Niu S, et al. N6(−)-methyladenosine mRNA methylation of PIK3CB regulates AKT signalling to promote PTEN-deficient pancreatic cancer progression. Gut. 2020;69:2180–92.
124. Chen M, Wang CM. The emerging roles of N6-methyladenosine (m6A) deregulation in liver carcinogenesis. Mol Cancer. 2020;19:44.
125. Gu Z, Du Y, Zhao X, Wang C. Diagnostic, Therapeutic, and Prognostic Value of the m6A Writer Complex in Hepatocellular Carcinoma. Front Cell Dev Biol. 2020;10:820111.
126. Li Z, Li F, Peng Y, Yang J, Zhou J. Identification of three m6A-related mRNAs signature and risk score for the prognostication of hepatocellular carcinoma. Cancer Med. 2020;9:1877–89.
127. Liu X, Qin J, Gao T, Li C, Chen X, Zeng K, Xu M, He B, Pan B, Xu X, et al. Analysis of METTL3 and METTL14 in hepatocellular carcinoma. Aging (Albany NY). 2020;12:21638–59.
128. Wu X, Zhang X, Tao L, Dai X, Chen P. Prognostic Value of an m6A RNA Methylation Regulator-Based Signature in Patients with Hepatocellular Carcinoma. Biomed Res Int. 2020;2020:2053902.
129. Wang J, Zhang Y, Song H, Yin H, Jiang T, Xu Y, Liu L, Wang H, Gao H, Wang R, Song J. The circular RNA circSPARC enhances the migration and proliferation of colorectal cancer by regulating the JAK/STAT pathway. Mol Cancer. 2021;20:81.
130. Weitz J, Koch M, Debus J, Hohler T, Galle PR, Buchler MW. Colorectal cancer. Lancet. 2005;365:153–65.
131. Shi J, Colorectal cancer. Nature. 2015;521:51.
132. Liu X, Liu L, Dong Z, Li J, Yu Y, Chen X, Ren F, Cui G, Sun R. Expression patterns and prognostic value of m6A-related genes in colorectal cancer. Am J Transl Res. 2019;11:3972–91.
133. Zhang Q, Cai Y, Kurkova V, Khan SA, Lu L, Zhang Y, Johnson CH. Gene Alterations of N6-Methyladenosine (m6A) Regulators in Colorectal Cancer. A TCGA Database Study. Biomed Res Int. 2020;2020:8826456.
134. Sun H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209–49.
135. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7–30.
136. Siegel RL, Miller KD, Goding SA, Fedewa SA, Butterly LF, Anderson HC, Cercek A, Smith RA, Jemal A. Colorectal cancer statistics, 2020. CA Cancer J Clin. 2020;70:145–64.
137. Chen W, Zheng R, Zeng S, Zeng H, Xia C, Zuo T, Yang Z, Zou X, He J. Cancer incidence and mortality in China, 2013. Cancer Lett. 2017;401:63–71.
138. Mihalce A, Alcala S, Martin-Hijano L, Cabexa-Sainz P, Navarro D, Munoz ER, Yuste L, Tivary K, Walter K, Ruiz-Canas L, et al. Exploiting oxidative phosphorysis to promote the stem and immuneovasive properties of pancreatic cancer stem cells. Nat Commun. 2020;11:5265.
139. Sharma GG, Okada Y, Von Hoff DD, Goel A. Non-coding RNA biomarkers in pancreatic ductal adenocarcinoma. Semin Cancer Biol. 2021;75:153–68.
140. Rahib L, Smith BD, Aizenberg AZ, Rosenzweig AB, Fleshman JM, Patrinos LM. Projecting cancer incidence and deaths to 2030 the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74:2913–21.
141. Geng Y, Guan R, Hong H, Huang B, Liu P, Guo X, Hu S, Yu M, Hou B. Identification of m6A-related genes and m6A RNA methylation regulators in pancreatic cancer and their association with survival. Ann Transl Med. 2020;8:387.
142. Xu F, Zhang Z, Yuan M, Zhao Y, Zhou Y, Pei H, Bai L. m6A Regulatory Genes Play an Important Role in the Prognosis, Progression and Immune Microenvironment of Pancreatic Adenocarcinoma. Cancer Invest. 2021;39:39–54.
143. Zhang N, Hua X, Tu H, Li J, Zhang Z, Max C. Isohapontigenin (ISO) inhibits EMT through FOXO3A/METTL14/VIMENTIN pathway in bladder cancer cells. Cancer Lett. 2021;520:400–8.

**Publisher’s Note**
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.